Editorial p951 Redefining outcomes in asthma—remission and beyond The Lancet Respiratory Medicine +++ +...

Morphine for chronic breathlessness (MABEL) in the UK: a multi-site, parallel-group, dose titration, double-blind, randomised, placebo-controlled trial https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(25)00205-X/fulltext?dgcid=hubspot_update_feature_updatealerts_lanres&utm_campaign=update-lanres&utm_medium=email&_hsenc=p2ANqtz-9JrwrNBHrwVOJyH_r9i1e9Ndy3BAE1kD75rgt2rDZSg7ta3aMBHB7Du12e2F3EBwBHa6t12tOgoKmmP370-vRHx1Jqiw&_hsmi=389230073&utm_content=388873256&utm_source=hs_email Taladegib for the treatment of idiopathic pulmonary fibrosis (ENV-IPF-101): a multicentre, randomised, double-blind, placebo-controlled, phase 2a trial https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(25)00239-5/abstract?utm_campaign=update-lanres&utm_medium=email&dgcid=hubspot_update_feature_updatealerts_lanres&_hsenc=p2ANqtz-9Lzv18LrGtp4VJ3RunQYa_6J8KHfXm672-LmeDYk05ox6_Ngm68p8YiaRp4F1XEGKeuHL3zp9F4De0JbWUM61YOK0L1w&_hsmi=389230073&utm_content=388873256&utm_source=hs_email Sweat chloride and lung function responses to elexacaftor–tezacaftor–ivacaftor in people with cystic fibrosis with two versus one responsive CFTR variants: an analysis of two real-world observational studies https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(25)00190-0/abstract?utm_campaign=update-lanres&utm_medium=email&dgcid=hubspot_update_feature_updatealerts_lanres&_hsenc=p2ANqtz-9ZQHQEXWh1HMM1DDgS7HMAOmx9qulQidMFJ9qFoyMVajBcVcELftcU_hx8rhcwunjAv9oE8HFqTo2Ix58qu2XsEj0HCA&_hsmi=389230073&utm_content=388873256&utm_source=hs_email Editorial p951 Redefining outcomes in asthma—remission and beyond The Lancet Respiratory Medicine https://www.thelancet.com/journals/lanres/issue/vol13no11/PIIS2213-2600(25)X0011-4